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Background: Faster formation of dense and poorly lyzable fibrin networks have been reported in patients 
at risk of thromboembolism, including cancer patients. We sought to investigate whether chemotherapy 
affects plasma fibrin clot properties and their determinants in lung cancer patients. 
Methods: In this observational study we enrolled 83 consecutive patients with advanced inoperable 
lung cancer. Plasma fibrin clot permeability (Ks), turbidimetric analysis of clot formation, clot lysis time 
(CLT), microparticle-associated tissue factor (MP-TF) activity, and thrombin generation parameters were 
investigated at enrolment and 3–4 months after standard chemotherapy. 
Results: Lung cancer patients after 4 (range, 4–5) cycles of chemotherapy had 35.6% higher D-dimer, 
22.1% lower MP-TF activity, and unaltered fibrinogen compared with baseline. Chemotherapy resulted 
also in 7.5% increased Ks, 8.6% prolonged lag phase, and 5.4% shortened CLT, while thrombin generation 
was unchanged. Chemotherapy-related differences in clot structure were confirmed by scanning electron 
microscopy images. Fibrin clot properties after chemotherapy did not differ among histological types of lung 
cancer, cancer stages or chemotherapy regimens. Interestingly, never smoking (n=13, 16%) was associated 
with looser post-treatment fibrin structure as reflected by 12.3% higher Ks. Multiple linear regression 
showed that more advanced cancer stage, higher peak thrombin generation, and higher white blood cell 
count determined post-treatment change in Ks, while active smoking was associated with change in CLT. 
Conclusions: Three-month chemotherapy in lung cancer patients improves clot properties despite 
unaffected thrombin generation, suggesting that anticancer treatment might quickly produce antithrombotic 
actions.
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Introduction
Lung cancer is the leading cause of cancer death among 
both men and women (1), however available treatment, 
including palliative strategies, significantly prolongs the 
life of patients with advanced lung cancer (2). Despite the 
introduction of new therapies such as chemotherapy and 
immunotherapy that in some cases make cancer a chronic 
disease, lung cancer remains the most prevalent fatal 
tumour (3). Approximately 3% of lung cancer patients 
develop venous thromboembolism (VTE) within 2 years 
since diagnosis (4) with a year cumulative incidence of 
10.2% in patients with small cell lung carcinoma (SCLC) (5) 
and about 22% in those with non-small cell lung carcinoma 
(NSCLC), which accounts for more than 80% lung 
cancers (6,7). A hypercoagulable state in lung cancer 
involves tissue factor (TF), microparticles, anticoagulant 
and antifibrinolytic systems, platelets, and many other 
factors (8). The lung cancer chemotherapy is associated 
with three-fold increased risk for VTE (9). An imbalance 
between coagulation activation and fibrinolytic potential 
might contribute to thromboembolic complications during 
chemotherapy. Shortening of clotting time, increase 
in antithrombin levels and thrombin-antithrombin 
complexes, followed by decreased plasma D-dimer, 
plasmin-α2-antiplasmin complex and fibrinogen levels 
have been observed in lung cancer patients during the 
first and the second cycle of standard anticancer therapy 
with a large variability of these parameters up to 3 weeks 
after treatment (10). Recent study has demonstrated that 
activated and apoptotic platelets, together with platelet-
derived microparticles contribute to hypercoagulable state 
in patients with NSCLC after chemotherapy and can be 
closely related to thromboembolic complications during 
anticancer treatment (11).
Growing evidence indicates that the formation of 
clots composed of compact fibrin networks resistant to 
fibrinolysis, which is largely determined by environmental 
factors (12), predisposes to VTE (13). Cigarette smoking, 
a common risk factor for lung cancer, also negatively alters 
fibrin clot properties (14). Data on fibrin clot characteristics 
in cancer patients, however, are scarce. Less permeable 
fibrin clots relatively resistant to lysis have been observed 
in gastrointestinal cancer and multiple myeloma (15,16). 
Rheometry of blood clots in lung cancer patients has shown 
the formation of pathological clot microstructure with 
changes of physical properties, including higher fractal 
dimension in patients with extensive lung cancer compared 
with the localized disease (17). 
To our knowledge, comprehensive analysis of the plasma 
clot formation, permeability, and lysis in patients with 
advanced lung cancer during chemotherapy has not been 
published so far. Therefore, we investigated plasma fibrin 
clot features and their determinants in lung cancer patients 
before and after chemotherapy.
Methods 
Study population
From May to September 2014 in a prospective study we 
evaluated 83 white consecutive patients with advanced 
histologically or cytologically confirmed lung cancer 
who were recruited at the Department of Oncology, 
the John Paul II Hospital, Cracow, Poland. Patients 
were categorized into subjects with SCLC and those 
with NSCLC that included three main subtypes: 
adenocarcinoma, squamous cell cancer, and not otherwise 
specified (NOS) carcinoma, involving cases other than 
adenocarcinoma, squamous cell, large cell carcinoma or 
mixed/other histology. 
The American Joint Committee on Cancer (AJCC) 
stages were determined according to the AJCC 7th 
edition staging system, using available clinical data. 
Initially all patients met all the following eligibility criteria 
for chemotherapy: an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 or 1; adequate 
organ function (leukocytes ≥3,000/μL and ≤12,000/μL; 
neutrophils ≥1,500/μL; platelets ≥100,000/μL; haemoglobin 
≥9.0 g/dL; total  bi l irubin ≤1.5 mg/dL; aspartate 
aminotransferase and alanine aminotransferase ≤2.5× upper 
limit of normal; serum creatinine ≤1.5 mg/dL or creatinine 
clearance ≥60 mL/min; PaO2 ≥60 mmHg).
The exclusion criteria were: any active infections, 
glomerular f i l trat ion rate <60 mL/min,  hypo- or 
hyperthyroidism, any acute vascular events, and current 
anticoagulant therapy. Patients in whom prophylaxis with 
low-molecular-weight heparins (LMWH) was administered, 
were eligible.
Heart failure (HF) was defined as the presence of relevant 
symptoms and signs and left ventricular ejection fraction 
≤45%. Arterial hypertension was diagnosed based on a 
history of hypertension (blood pressure >140/90 mmHg) 
or preadmission antihypertensive treatment. Diabetes 
mellitus was defined as fasting glucose ≥7.0 mM on two 
separate occasions or use of insulin or oral hypoglycaemic 
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agents. Coronary artery disease (CAD) was defined as 
hospitalization for angina, prior documented myocardial 
infarction or coronary revascularization. Ischemic stroke 
was diagnosed based on the World Health Organization 
criteria. Chronic obstructive pulmonary disease was defined 
by the presence of irreversible expiratory airflow limitation 
measured by spirometry. Current smoker was defined as 
a subject who has smoked 100 cigarettes and currently 
declares the use of one or more cigarettes per day, while 
former smoker as a person who has smoked at least 100 
cigarettes in a lifetime, but currently (at least within the last 
month) does not smoke.
All patients commenced standard chemotherapy according 
to the histopathological type of cancer and co-morbidities 
(18). Patients on chemotherapy underwent standard chest 
computed tomography scans at the 9th or 12th week since 
its onset and were assessed according to the response 
evaluation criteria in solid tumours (RECIST 1.1) (19). The 
recommended thromboprophylaxis in high-risk patients was 
administered (20). 
The Local Ethical Committee in Krakow approved 
the study (31/KBL/OIL/2013) and participants provided 
informed consent in accordance with the Declaration of 
Helsinki.
Laboratory investigations
Fasting blood samples were drawn from antecubital vein 
using minimal stasis. Blood samples were drawn at the time 
of enrolment before starting chemotherapy and before 
the third or fourth cycle of chemotherapy. Patients who 
received prophylactic LMWH were drawn at least 12 hours 
since the injection. Complete blood count, glucose and 
creatinine were assayed by routine laboratory techniques. 
Fibrinogen was determined using the Clauss method. 
Plasma D-dimer was measured with the Innovance D-dimer 
assay (Siemens, Marburg, Germany). Immunoenzymatic 
assay was used to determine the TF-bearing microparticles 
(MP-TF) activity (Hyphen BioMed, Neuville sur Oise, 
France).
Fibrin clot properties
In citrated plasma (vol/vol, 9:1 of 3.2% sodium citrate), 
the following variables describing a plasma clot formation, 
structure and lyzability were determined in duplicate by 
technicians blinded to the origin of the samples (intra-assay 
and inter-assay coefficients of variation, 5% to 7%).
Clot permeability
Permeation of plasma fibrin clots was determined as 
described (21). Briefly, 20 mM calcium chloride and 
1 U/mL human thrombin (Sigma-Aldrich, St. Louis, MO, 
USA) were added to citrated plasma. Tubes containing 
the clots were connected to a reservoir of a Tris-buffered 
saline (TBS; 0.01 M Tris, 0.1 M NaCl, pH 7.4) and its 
volume flowing through the gels was measured. A permeation 
coefficient (Ks), which indicates the pore size, was calculated 
from the equation: Ks = QxLxη/txAxΔp, where Q is the flow 
rate in time t, L is the length of a fibrin gel, η is the viscosity of 
liquid (in poise), t is percolating time, A is the cross-sectional 
area (in cm2) and Δp is a differential pressure (in dyne/cm2). 
After Ks measurement clots (n=6) were fixed using 2.5% 
glutaraldehyde, then removed from tubes, washed with 
distilled water, dehydrated in graded water-ethanol solutions, 
dried by the critical point procedure and sputter coated with 
gold. Samples were scanned in six different areas (microscope 
JEOL JCM-6000; JEOL Ltd., Tokyo, Japan).
Turbidity measurements
Plasma citrated samples were mixed 2:1 with a TBS 
containing 0.6 U/mL human thrombin (Sigma-Aldrich) 
and 50 mM CaCl2 to initiate polymerization. Absorbance 
was read at 405 nm with a Perkin-Elmer Lambda 4B 
spectrophotometer (Molecular Devices). The lag phase of 
the turbidity curve, which reflects the time required for 
initial protofibril formation and maximum absorbance at the 
plateau phase (ΔAbs), indicating the number of protofibrils 
per fiber, were recorded (21).
Clot lysis assay 
Clot lysis  t ime (CLT) was measured as described 
previously (21). Briefly, to 75 μL of citrated plasma we 
added TF (dilution 105 times; Innovin, Dade Behring, 
Deerfield, IL, USA), CaCl2 (final concentration, 17 mM), 
tissue plasminogen activator (tPA, final concentration, 
30 U/mL; Boehringer Ingelheim, Ingelheim, Germany) and 
phospholipid vesicles (22) (final concentration, 10 mM). 
HEPES buffer was added to make a total volume of 150 μL.
Thrombin generation assay 
To assess the thrombin generation profiles, we used the 
assay previously described (23,24). Briefly, corn trypsin 
inhibitor was added to citrated plasma (0.1 mg/mL, final 
concentration) and 80 μL of the sample was mixed with 
relipidated TF (5 pM, final concentration). Twenty µL of a 
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2.5 mM Z-GGR-AMC/90 mM CaCl2 solution in HEPES 
was added. Twenty μL of a 120 μM phospholipid vesicles 
solution in HEPES was then added to plasma samples to 
achieve a final concentration of 20 µM, thus initiating thrombin 
generation. Hydrolysis of the AMC substrate (at 370/460 nm) 
was followed over a 3,600 s period. Changes in fluorescence 
were converted to thrombin concentration using a calibration 
curve built by sequential dilutions of human thrombin.
Statistical analysis
The study was powered to have a 90% chance of detecting 
a 10% difference in CLT using a P value of 0.01, based 
on the previous study (25). In order to demonstrate such 
a difference, or a greater one, 32 patients or more were 
required in each group. In turn, to demonstrate such a 
difference, or a greater one, in Ks using a P value of 0.05 at 
least 31 patients were required in each group (22).
Variables were presented as mean and standard deviation, 
median and interquartile range or otherwise stated. The 
normality of distribution was checked using Shapiro-
Wilk test. The Spearman’s rho correlation coefficient was 
computed to measure the relationship between continuous 
variables. For testing association for categorical variables, 
the Fischer’s Exact test was used. The t-test was used for 
means comparison, whereas the non-parametric U Mann-
Whitney or Kruskal-Wallis tests were used for comparison 
of non-normally distributed variables. For paired data the 
paired Student’s t-test or the Wilcoxon signed-rank tests 
were used as appropriate. 
∆Ks and ∆CLT were calculated as a difference in Ks 
values after 3-month chemotherapy and baseline, and the 
difference in the CLT values between baseline and after 
3-month chemotherapy, respectively. Higher ∆Ks and 
∆CLT denote improved clot permeability and lyzability, 
respectively. Determinants of ∆Ks and ∆CLT were 
established in a multiple linear regression model, built 
by a forward stepwise selection procedure, and verified 
by F Snedecor’s statistics, with F >1. The R2 was used as 
a measure of the variance. The models were adjusted for 
fibrinogen. All statistical analyses were performed with 
JMP®, version 12.2.0 (SAS Institute INC., Cary, NC, USA).
Results
Patient characteristics
Baseline characteristics of lung cancer patients before and 
after therapy are summarized in Table 1. At enrolment 37 
(44.6%) patients were diagnosed with the SCLC and 46 
(55.4%) with the NSCLC. Metastatic lung cancer was 
diagnosed in 53 (63.9%) patients, while in 30 (36.1%) 
locally advanced inoperable lung cancer was recognized. 
The study group included 37 patients with limited disease 
(LD) and 46 patients with extended disease (ED). 
Patients with NSCLC before chemotherapy had higher 
peak thrombin {181 [108–247] vs. 135 [97–148] nM, 
P=0.043} and D-dimer {528 [351–1,085] vs. 324 [254–691] 
ng/mL, P=0.017} levels than those with SCLC, while 
patients with stage IV/ED were characterized by higher 
D-dimer {638 [396–1,174] vs. 326 [254–495] ng/mL, 
P<0.0001} and MP-TF activity [1.74 (1.24–2.40) vs. 1.30 
(0.89–1.90) pg/mL, P=0.032] compared to those with stage 
III/LD.
Impact of chemotherapy
Among 83 patients who completed at least 4 [median, 
5 (range, 4–5)] cycles of chemotherapy, 12 (14.5%) 
subjects were treated with cisplatin/vinorelbine, one 
subject (1.2%) with cisplatin/gemcitabine, 5 (6%) subjects 
with carboplatin/vinorelbine, 13 (15.7%) with paclitaxel/
carboplatin,  10 (12%) with cisplatin/pemetrexed, 
1 (1.2%) with vinorelbine in monotherapy, 23 (27.7%) 
with cisplatin/etoposide and 17 (20.5%) with carboplatin/
etoposide. In one (1.2%) patient the tyrosine kinase 
inhibitor was administered. Among lung cancer patients, 
54 (65%) individuals responded to treatment, 21 (25%) had 
disease stabilization and 8 (10%) had cancer progression. 
Interestingly, CLT assessed before chemotherapy was 
significantly associated with the clinical response to 
treatment and was prolonged in patients with the disease 
progression and shortened in those with the response to 
chemotherapy (P value for ANOVA =0.038; Figure 1). No 
symptomatic thromboembolic events were observed.
Three months after the onset of chemotherapy we found 
17.5% lower red blood cell count, 28.6% lower white blood 
cell count, 15.5% lower haemoglobin, along with 35.6% 
higher D-dimer and 22.1% lower MP-TF activity, while 
fibrinogen was unaltered. Interestingly, we observed 7.5% 
increased Ks, 8.6% prolonged lag phase, 5.4% shortened 
CLT and unchanged thrombin generation parameters 
(Table 1). As reflected by the SEM analysis, along with the 
clot permeability, patients after chemotherapy had more 
porous fibrin structure (Figure 2). Patients with NSCLC 
compared to those with SCLC had higher glucose levels, 
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Table 1 Laboratory tests and fibrin clot variables in lung cancer patients before and after chemotherapy
Variable Lung cancer patients (n=83)
Patients after 3-month chemotherapy 
(n=83)
P value
Age, years 63.9±7.0 – –
Male, n (%) 51 (61.4) – –
Body mass index, kg/m2 25.3±4.6 – –
Current smoking, n (%) 42 (50.6) – –
Previous stroke, n (%) 3 (3.6) – –
CAD, n (%) 14 (16.9) – –
Arterial hypertension, n (%) 41 (49.4) – –
Diabetes, n (%) 9 (10.8) – –
COPD, n (%) 13 (15.7) – –
Statin, n (%) 19 (22.9) – –
ACEI, n (%) 19 (22.9) – –
Aspirin, n (%) 16 (19.3) – –
RBC, 106/µL 4.51±0.46 3.73±0.52 <0.001
WBC, 103/µL 9.0 [7.2–11.4] 6.5 [5.1–9.0] <0.001
Platelets, 103/µL 313 [256–366] 324 [221–394] 0.92
Haemoglobin, g/dL 12.9±1.5 10.9±1.4 <0.001
Glucose, mM 5.3 [4.9–6.0] 5.5 [5.1–6.1] 0.40
Creatinine, µM 74 [62–84] 77 [67–90] 0.075
Fibrinogen, g/L 3.15 [2.70–3.90] 3.22 [2.65–3.77] 0.83
D-dimer, ng/mL 491 [303–893] 666 [496–940] 0.013
MP-TF activity, pg/mL 1.49 [0.98–2.20] 1.16 [0.83–1.59] 0.034
Ks, 10
−9 cm2 6.7 [5.8–7.5] 7.2 [6.7–7.6] 0.00011*
Lag phase, s 39.98±3.96 43.42±4.04 <0.001*
ΔAbs (405 nm) 0.85 [0.80–0.90] 0.84 [0.78–0.88] 0.80*
Clot lysis time, min 98.0±16.8 92.7±15.2 0.031*
Lag time, s 1,177 [1,028–1,483] 1,119 [917–1,301] 0.18
Peak thrombin generated, nM 144 [98–223] 136 [99–205] 0.22
TTPeak, s 2,139 [1,854–2,585] 2,063 [1,740–2,386] 0.97
ETP, nM·s 94,346±37,237 91,744±35,278 0.095
*, adjusted for fibrinogen. Data are given as mean ± SD, n (%), or median [interquartile range]. COPD, chronic obstructive lung disease; 
CAD, coronary artery disease; HF, heart failure; ACEI, angiotensin-converting enzyme inhibitors; RBC, red blood cells; WBC, white blood 
cells; MP-TF, tissue factor-bearing microparticles procoagulant activity; Ks, fibrin clot permeability; ΔAbs (405 nm), maximum absorbance 
of fibrin gel at 405 nm; TTPeak, time to thrombin peak; ETP, endogenous thrombin potential.
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peak thrombin generated, and ETP, while subjects with 
stage ED/IV had higher D-dimer levels and peak thrombin 
generated than those with LD/III (Table 2). None of the 
analysed variables differed significantly between patients 
receiving various chemotherapy combinations (data not 
shown). Fibrin clot properties after chemotherapy were 
similar in patients with different histological types of lung 
cancer or cancer stages (Table 2). Notably, Ks, but not other 
fibrin or thrombin generation variables, was higher after 
chemotherapy in never smoking patients (n=13, 16%) 
compared with current and former smokers [8.1 (7.5–8.2) 
vs. 7.1 (6.7–7.5) ×10−9 cm2, P=0.046]. Post-treatment Ks 
was associated with the pack-years (r=−0.29, P=0.016) and 
with MP-TF activity (r=−0.23, P=0.037). Peak thrombin 
generated correlated with Ks, WBC count, and D-dimer 
(r=−0.31, P=0.0091; r=0.46, P<0.001 and r=−0.29, P=0.015, 
respectively), while ETP was associated with WBC only 
(r=0.31, P=0.0071). 
The multiple linear regression model showed that 
stage ED/IV (B=−0.31; 95% CI: −0.57 to −0.056; R2=33, 
P<0.0001), peak thrombin generated (B per 10 nM =−0.030; 
95% CI: −0.059 to −0.001; R2=39, P<0.0001), and white 
blood cell count (B per 103/µL =−0.082; 95% CI: −0.15 
to −0.011; R2=32, P<0.0001) determined ∆Ks, while active 
smoking determined ∆CLT (B=−4.95 min; 95% CI: −9.64 
to −0.27 min; R2=0.37, P<0.0001).
Discussion
Recently, we have demonstrated that the prothrombotic 
plasma clot phenotype, including faster formation of fibrin 
clots, reduced fibrin network porosity and impaired clot 
lyzability, characterizes patients with advanced lung cancer, 
including locally advanced inoperable disease and disseminated 
disease (Abstract No. PB 912 at the XXVIth Congress of the 
ISTH). The current study is the first to show that a 3-month 
chemotherapy in lung cancer patients has a favourable effect 
on fibrin clot properties, including slower formation of 
less compact fibrin networks, despite unaltered persistently 
elevated thrombin generation. Our study provides new insights 
into the mechanisms of a hypercoagulable state in lung cancer 
patients during chemotherapy (9), suggesting the presence of 
additional favourable fibrin-related changes, in part determined 
by the disease stage, thrombin generation potential, and 
smoking habit.
A slight but significant improvement in fibrin clot 





















Figure 1 Associations between CLT and response to chemotherapy 
in lung cancer patients. 0, denotes cancer progression; 1, disease 
stabilization; 2, any response to treatment. Data are given as 
median (interquartile range). CLT, clot lysis time.
Figure 2 Representative scanning electron microscopy (SEM) 
images of plasma fibrin networks in a representative lung cancer 
patient before (A) and after chemotherapy (B). Magnification, 
5,000×; fibrinogen concentration, 3 g/L. Ks =6.3×10
−9 cm2 
before chemotherapy (A) and Ks =7.4×10
−9 cm2 after anticancer 
treatment (B).
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in advanced lung cancer patients was a surprising finding, 
since typically anticancer therapy is associated with a 
hypercoagulable state reflected by increased fibrinogen and 
D-dimer levels (9,26). In our previous study performed in 
multiple myeloma patients induction therapy led to higher 
Ks and shortened CLT associated with a reduction in peak 
thrombin generated (27). In advanced cancer patients, no 
such associations were observed. Thrombin and TF have 
been postulated to represent key mediators of cancer-
related thrombosis in general (28). Reitter et al. (29) 
have shown that peak thrombin generated decreased in 
lung cancer patients at different disease stages over time, 
while D-dimer levels increased during chemotherapy. 
The authors examined, however, less than one third of 
patients with the advanced disease (29). We observed no 
significant differences regarding thrombin generation in 
the current study, which might suggest that 3 months of 
chemotherapy in patients with advanced inoperable lung 
cancer has a negligible impact on thrombin formation, 
but MP-TF activity was reduced by 22% after treatment. 
Increased circulating levels of MPs have been shown in 
lung cancer patients compared with healthy controls (30). 
Highly elevated MP-TF activity was also found in patients 
with metastatic pancreatic cancer, with its moderate inverse 
association with time to fibrin clot formation (31). Few 
studies have evaluated MP-TF activity in lung cancer 
patients (17). We found a weak association of MP-TF with 
Ks after treatment, which suggests an additional harmful 
effect of elevated MP-TF activity and its contribution to the 
formation of denser, more prothrombotic fibrin networks. 
This observation is novel and might have a large impact 
in other non-cancer clinical settings. The current study 
provides additional evidence that a coagulation potential 
of TF-bearing MPs might contribute to the multifactorial 
hypercoagulability in lung cancer patients. 
We confirmed the strong impact of smoking on plasma 
clot structure in lung cancer patients, which highlights a 
major prothrombotic effect of this factor, potent enough 
to be observed despite a highly prothrombotic state in 
cancer. Cigarette smoking, in particular in heavy smokers, 
increases thrombotic risk via multiple mechanisms, 
including hyperfibrinogenaemia or enhanced oxidative 
stress leading to impaired fibrin permeability and lysis (32). 
We demonstrated that the active or former smoking was 
associated with about 12% lower Ks after chemotherapy, 
which indicates that negative effects of smoking on clot 
properties are still detectable during chemotherapy. Of note, 
these effects of smoking were not related to differences in 
fibrinogen concentrations or thrombin generation. Our 
observation regarding smoking underscores the value of 
recommendations to quit smoking in cancer and non-cancer 
patients, also in order to positively impact prothrombotic 
tendencies. We showed that no smoking can determine a 
more favourable post-treatment clot feature. It has also been 
reported that never smokers with NSCLC had higher response 
rates to chemotherapy, lower rates of progressive disease and 
longer survival than current and former smokers (33). Based 
on the current evidence, it might be speculated that less 
prothrombotic fibrin clot phenotype might also be related 
to a better outcome during anticancer therapy.
Recently, it has been suggested that platelets might play 
an important role in hypercoagulable state development 
after chemotherapy (11). Platelets behind blood coagulation 
are involved in angiogenesis and cancer growth by secretion 
of multiple growth factors and chemoattractants, including 
platelet factor 4 (34,35). In vitro experiments on platelets 
treated with cisplatin showed that anticancer drugs can 
lead to increased production of intrinsic activated factor 
X, followed by elevated thrombin generation and fibrin 
formation (11). Thrombin formation and fibrin generation 
were increased 1 day after chemotherapy and returned 
to the baseline (day 0) after one week in a model using 
platelet-free plasma mixed with platelets isolated from 
blood of lung cancer patients (11). How important is the 
platelet activation in the development of thromboembolic 
complications in cancer patients in the light of our data 
showing favourable changes in fibrin properties after 
chemotherapy needs further investigation.
This study has several limitations. First, the sample size 
was limited. The study was, however, adequately powered 
to detect intergroup differences in clot variables, although 
the subgroup analyses should be interpreted with caution. 
Second, the present cohort included various histological 
types of lung cancer and treatment with a few regimens, 
however such group is representative for this disease at its 
advanced stage. Third, an assessment of platelet activation 
was beyond the scope of this study.
In conclusion, advanced lung cancer unfavourably 
alters plasma clot properties, including faster formation 
of more compact clots displaying impaired lyzability, but 
chemotherapy improves these properties. Clinical relevance 
of the current findings remains to be explored.
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